Current Report Filing (8-k)
October 28 2020 - 6:02AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 26, 2020
Alterola Biotech Inc.
(Exact name of registrant as specified in its charter)
Nevada
|
333-156091
|
TBA
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
340 S Lemon Ave #4041,
Walnut CA
|
91789
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: 512-821-2121
___________________________________________________
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
Section 5 – Corporate Governance
and Management
Item 5.03 Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year
Amended to Articles
of Incorporation
On October 26, 2020,
the board of directors and majority shareholders of the Company approved an amendment of the Company's Articles of Incorporation
to increase the authorized common stock from 500,000,000 shares to 2,000,000,000 shares, par value $0.001 per share.
A copy of the Certificate
of Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Amended and Restated
Bylaws
On October 26, 2020,
the board of directors approved an amendment and restatement of the Company's bylaws. The bylaws were amended and restated to allow
a majority of directors to act by written consent in lieu of a meeting.
A copy of the Amended
and Restated Bylaws is attached hereto as Exhibit 3.2 and incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
|
Item 9.01
|
Financial Statements and Exhibits
|
3.1 Certificate of Amendment
3.2 Amended and Restated Bylaws
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alterola Biotech, Inc.
/s/ Larson Elmore
Larson Elmore
Chief Executive Officer
Date: October 27, 2020
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Apr 2023 to Apr 2024